Centrus Energy Corp.
LEU
$152.31
-8.18%
Centrus Energy Corp. supplies nuclear fuel and related technical services to the nuclear power industry, operating through a Low-Enriched Uranium (LEU) segment that sells separative work units (SWU) and uranium, and a Technical Solutions segment providing engineering, design, and manufacturing services to government and private customers, with the vast majority of revenue generated in the United States. The company occupies a uniquely strategic position as the only U.S.-based producer of high-assay low-enriched uranium (HALEU), giving it a quasi-monopoly on a critical input for the next generation of advanced nuclear reactors and small modular reactors. The current investor narrative centers on this HALEU franchise, a reported record backlog near $3.9 billion, and roughly $900 million in U.S. government support, all framed against the AI-driven electricity demand boom that is reviving nuclear power economics. Offsetting this bullish thesis are persistent concerns about the pending expiration of legacy Russian supply contracts, lumpy and unpredictable quarterly earnings, and a stock that has fallen sharply from its highs even as the long-term demand story strengthens.…
LEU
Centrus Energy Corp.
$152.31
Related headlines
Investment Opinion: Should I buy LEU Today?
Rating: Hold. Centrus Energy presents a compelling long-term growth story as the only U.S. HALEU producer with a $3.9 billion backlog and $900 million in government support, but the current valuation and negative free cash flow warrant a cautious stance. The analyst consensus is 'buy' with an average target of $248.28 (63% upside), yet the majority of recent ratings are Neutral, and the stock is in a severe downtrend, down 44.1% YTD.
The supporting evidence is mixed. On the positive side, the company has a fortress balance sheet with $1.87 billion in cash and a current ratio of 5.59, and the Oklo supply agreement validates its HALEU franchise. However, revenue growth is decelerating (4.9% YoY in Q1 2026), trailing free cash flow is -$61.4 million, and the valuation is rich at 9.72x PS and 40.5x forward PE. The forward PE implies 38% earnings growth, which is a high bar given the lumpy revenue pattern.
The biggest risks are execution delays in the HALEU ramp, the expiration of Russian supply contracts, and continued cash burn. The rating would upgrade to Buy if the stock breaks above $185 (intermediate resistance) and revenue growth accelerates above 15%, or if free cash flow turns positive. It would downgrade to Sell if the stock breaks below $142.13 (52-week low) or if the HALEU program faces significant delays. Relative to its own history, the stock is in the middle-to-lower portion of its valuation band, but it remains overvalued relative to peers and its growth rate.
Sign up to view all
LEU 12-Month Price Forecast
Centrus Energy is a high-risk, high-reward story stock with a unique HALEU monopoly and a $3.9 billion backlog, but the financials have yet to reflect the bullish narrative. Revenue growth is anemic at 4.9%, free cash flow is deeply negative, and the valuation is rich at 9.72x sales and 40.5x forward earnings. The analyst consensus is bullish, but the wide target range and heavy Neutral ratings suggest low conviction. The technical picture is bearish, with the stock near its 52-week low and momentum deteriorating. I would upgrade to bullish if the company demonstrates accelerating revenue growth and positive free cash flow, and downgrade to bearish if the stock breaks below $142.13 or if HALEU milestones slip.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centrus Energy Corp.'s 12-month outlook, with a consensus price target around $247.40 and implied upside of +62.4% versus the current price.
Average Target
$247.40
0 analysts
Implied Upside
+62.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$169 - $340
Analyst target range
Coverage is robust for a company of this size, with 17 analysts contributing to a consensus recommendation of 'buy' and a recommendation mean of 1.84 (where 1.0 is a strong buy and 3.0 is a hold). The average target price of $248.28 implies roughly 63% upside from the current price of $152.31, a strikingly bullish consensus relative to the stock's recent price action. However, the sentiment is more nuanced than the headline suggests: the institutional ratings log shows a heavy skew toward 'Neutral' actions from major firms — B of A Securities, Roth Capital, UBS, Citigroup, and JP Morgan have all maintained Neutral ratings through 2026, with only Needham and B. Riley carrying Buy ratings. This divergence between a 'buy' consensus and a wall of Neutral ratings suggests the bullish average target is driven by a few high-conviction bulls while the majority of analysts remain on the sidelines. The target range is extremely wide, from a low of $168.77 (just 10.8% above the current price) to a high of $340.00 (123% above), a spread of more than 2x that signals very low conviction and high uncertainty about the company's trajectory. The high target of $340 likely assumes successful HALEU production scaling, conversion of the $3.9 billion backlog into revenue, and multiple expansion as the AI-nuclear narrative reaccelerates; the low target of $168.77 prices in continued execution delays, Russian contract expiration risk, and margin compression. Notably, the low target is still above the current price, implying that even the most bearish analyst sees the stock as undervalued — a rare configuration that could signal a contrarian buying opportunity, though the recent 8.2% single-day drop and 9.24-day short ratio suggest the market is not yet listening. The consensus 2026 revenue estimate of $616.5 million (range $530.7M-$697.1M) and EPS estimate of $3.02 (range $2.47-$3.53) provide the fundamental anchor, and the stock's ability to hit the midpoint of those estimates will be the key determinant of whether the wide target spread resolves upward or downward.
Bulls vs Bears: LEU Investment Factors
The bear case currently has stronger near-term evidence, given the stock's 44.1% YTD decline, negative free cash flow of -$61.4 million, and a valuation (9.72x PS, 40.5x forward PE) that is disconnected from 4.9% revenue growth. However, the bull case rests on a genuine monopoly in HALEU production, a $3.9 billion backlog, and $1.87 billion in cash, which provide a credible long-term growth narrative. The single most important tension is whether Centrus can convert its HALEU backlog into accelerating revenue and positive cash flow before its cash burn erodes investor patience. If the HALEU ramp delivers, the stock could re-rate sharply toward analyst targets; if execution stalls, the current valuation offers little support.
Bullish
- HALEU Monopoly with $3.9B Backlog: Centrus is the only U.S.-based producer of high-assay low-enriched uranium (HALEU), a critical input for advanced nuclear reactors and small modular reactors. Its reported record backlog of approximately $3.9 billion, combined with roughly $900 million in U.S. government support, provides multi-year revenue visibility that is rare for a company of its size.
- Analyst Consensus Sees 63% Upside: With 17 analysts covering the stock, the consensus recommendation is 'buy' (mean 1.84) and the average target price is $248.28, implying 63% upside from the current price of $152.31. Even the lowest analyst target of $168.77 sits 10.8% above the current price, suggesting that the most bearish sell-side view still sees the stock as undervalued.
- Fortress Balance Sheet with $1.87B Cash: Centrus holds $1.87 billion in cash and has a current ratio of 5.59, providing enormous liquidity to fund its HALEU buildout and weather quarterly cash burn. The company raised $384 million in equity in Q4 2025, further strengthening its financial position without immediate solvency risk.
- Strategic Oklo Supply Agreement: In June 2026, Centrus secured a long-term fuel supply agreement with Oklo, a leading advanced nuclear developer, directly addressing a major bottleneck in the U.S. advanced nuclear sector. This deal locks in future revenue and validates Centrus's HALEU production capabilities, as reflected in the stock's 12% single-day surge on the announcement.
Bearish
- Extreme Valuation on Slowing Growth: The stock trades at a trailing PE of 56.1x, forward PE of 40.5x, PS of 9.72x, and EV/EBITDA of 32.97x, yet Q1 2026 revenue grew only 4.9% year-over-year. A 9.72x sales multiple on 4.9% growth is a valuation that requires flawless execution and accelerating revenue to sustain, leaving little room for error.
- Negative Free Cash Flow and Cash Burn: Trailing free cash flow is -$61.4 million, with Q1 2026 operating cash flow of -$35.1 million and capex of $23.2 million driving a -$58.3 million quarterly FCF. Inventory built by $70.7 million as the company stockpiles fuel, and the negative FCF yield means the market is paying dearly for cash flows that do not yet exist.
- Lumpy and Decelerating Revenue: Revenue has been highly uneven: $73.1M, $154.5M, $74.9M, $146.2M, and $76.7M over the past five quarters, with Q1 2026 growing just 4.9% YoY. This pattern underscores that revenue is not compounding smoothly, making it difficult to justify a premium multiple.
- Russian Contract Expiration Risk: Centrus faces the pending expiration of legacy Russian supply contracts, which could disrupt its fuel supply chain and revenue stream. This risk is a key overhang on the stock and is cited by analysts as a reason for caution, contributing to the wide target price spread from $168.77 to $340.00.
LEU Technical Analysis
Centrus is in a clear and sustained downtrend, with the shares down 32.1% over the trailing year and 44.1% year-to-date, a stark reversal from the momentum that once carried the stock to a 52-week high of $464.25. At the current price of $152.31, the stock sits just 3.0% above its 52-week low of $142.13, meaning it is trading at roughly 3% of its 52-week range — a positioning that signals capitulation-like weakness rather than a healthy pullback, and one that invites the classic 'falling knife' caution even as it raises the possibility of deep-value accumulation. The 66.4% maximum drawdown from peak confirms that this is a broken uptrend, not a routine correction. Recent momentum has deteriorated further, with the stock down 17.7% over the past month and 6.3% over three months, both far worse than the S&P 500's -1.06% and +3.04% respective returns, producing relative strength readings of -16.6 and -9.4 points. The most alarming signal is the single-session plunge of 8.18% on September 11, which took the price from $165.87 to $152.31 on volume of roughly 1.1 million shares, suggesting institutional distribution rather than retail noise. With the 1-month decline steeper than the 3-month and 1-year declines, momentum is decelerating rather than stabilizing, and the short ratio of 9.24 days indicates that bearish positioning remains heavy and could fuel either further downside or a violent short squeeze on any positive catalyst. Key technical levels are now sharply defined: support rests at the 52-week low of $142.13, roughly 6.7% below the current price, while resistance is anchored at the 52-week high of $464.25, an enormous 205% above current levels, with intermediate resistance likely forming around the $185-$195 zone where the stock repeatedly failed in August. A breakdown below $142.13 would open the door to new multi-year lows and likely trigger additional momentum-driven selling, whereas a reclaim of $185 would be the first evidence of a trend reversal. The beta of 1.334 means the stock is roughly 33% more volatile than the broader market, so position sizing should be materially smaller than a market-weight allocation, and the 66.4% max drawdown illustrates the severe capital-impairment risk inherent in this name.
Beta
1.33
1.33x market volatility
Max Drawdown
-66.4%
Largest decline past year
52-Week Range
$142-$464
Price range past year
Annual Return
-32.1%
Cumulative gain past year
| Period | LEU Return | S&P 500 |
|---|---|---|
| 1m | -17.7% | -1.6% |
| 3m | -6.3% | +1.3% |
| 6m | -27.3% | +13.9% |
| 1y | -32.1% | +16.3% |
| ytd | -44.1% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LEU Fundamental Analysis
Centrus's revenue trajectory is lumpy and, on the most recent print, decelerating: Q1 2026 revenue of $76.7 million grew just 4.9% year-over-year, a sharp slowdown from the $146.2 million reported in Q4 2025 and the $154.5 million in Q2 2025. The sequential decline reflects the inherently uneven timing of SWU and uranium deliveries, but the multi-quarter pattern — $73.1M, $154.5M, $74.9M, $146.2M, $76.7M — underscores that revenue is not compounding smoothly. Within the segment mix, the product side ($44.6 million) and SWU sales ($41.6 million) dominate, while uranium sales of just $3.0 million and services of $32.1 million are secondary, meaning the investment case hinges almost entirely on the LEU fuel franchise and its future HALEU ramp. The 4.9% growth rate is far too modest to justify the premium multiple the stock has historically commanded, which is why the market has repriced the shares so aggressively. Profitability is positive but thin and volatile: Q1 2026 net income was $10.0 million on a 13.0% net margin, with gross margin of 38.7% and an operating margin of just 1.0% after $28.9 million in operating expenses. The gross margin has swung violently across recent quarters — 38.7% in Q1 2026, 23.9% in Q4 2025, and a negative -5.7% in Q3 2025 — reflecting the mix shift between high-margin SWU and low-margin uranium resale, and the trailing gross margin of 26.2% and operating margin of 11.2% sit below what a true monopoly supplier should earn. The company is profitable on a trailing basis (EPS of $0.018, ROE of 10.2%), but the razor-thin ROA of 0.016% shows how little the asset base is currently generating. The balance sheet is the strongest part of the story: a current ratio of 5.59 and cash of $1.87 billion provide enormous liquidity, though debt-to-equity of 1.59 and a debt ratio of 0.48 mean leverage is meaningful. The critical red flag is cash flow — trailing free cash flow is -$61.4 million, Q1 2026 operating cash flow was -$35.1 million, and capex of $23.2 million drove a -$58.3 million quarterly FCF, with inventory building by $70.7 million. The company is burning cash to stockpile fuel and fund its HALEU buildout, and while the $1.87 billion cash pile and a $384 million equity raise in Q4 2025 fund this internally for now, the negative FCF yield and 85.5x price-to-cash-flow ratio mean the market is paying dearly for cash flows that do not yet exist.
Quarterly Revenue
$76700000.0B
2026-03
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
38.7%
Latest Quarter
Free Cash Flow
$-61400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LEU Overvalued?
Because Centrus is profitable on a trailing basis (net income positive, EPS of $0.018), the PE ratio is the appropriate primary metric, and it tells a story of extreme valuation: the trailing PE is 56.1x while the forward PE is 40.5x, a gap that implies the market expects earnings to grow roughly 38% over the next year, consistent with consensus EPS of $3.02 versus the trailing $0.018. However, the trailing PE is distorted by a near-zero trailing EPS base, so the more informative multiples are the price-to-sales ratio of 9.72x and EV/EBITDA of 32.97x, both of which are extraordinarily rich for a company growing revenue at only 4.9%. The forward PE of 40.5x is the cleanest lens, and it still represents a substantial premium to the broader market and to most industrial peers. Peer comparison is difficult because Centrus has no direct U.S. comparable — it is effectively the only domestic HALEU producer — but against the broader energy and uranium complex, its 9.72x PS and 32.97x EV/EBITDA stand at dramatic premiums; a typical uranium miner or fuel-cycle company trades at a fraction of these multiples. The premium is partially justified by the genuine scarcity value of the HALEU monopoly and the $3.9 billion backlog, but a 9.72x sales multiple on 4.9% growth is a valuation that requires flawless execution and accelerating revenue to sustain. The PB ratio of 5.70x and PEG ratio of -15.7 (negative because of the distorted trailing earnings base) further illustrate that the stock is priced for a future that has not yet materialized in the financials. Historically, Centrus's valuation has been wildly unstable: the PS ratio ranged from 3.59x in Q2 2024 to 75.8x in Q3 2025, and the PE ratio swung from 5.19x in Q4 2024 to 369x in Q3 2025. The current PS of 9.72x and PE of 56.1x sit in the middle-to-lower portion of that historical band, meaning the stock has de-rated substantially from its bubble-era multiples but is not yet at the deep-value levels seen in 2024. This suggests the market has partially, but not fully, repriced the company's execution risk — leaving room for further downside if growth does not inflect, or meaningful upside if the HALEU ramp delivers.
PE
56.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.0x
Enterprise Value Multiple
Investment Risk Disclosure
Centrus faces significant financial and operational risks. The company is burning cash, with trailing free cash flow of -$61.4 million and Q1 2026 operating cash flow of -$35.1 million, driven by a $70.7 million inventory build and $23.2 million in capex. While $1.87 billion in cash and a 5.59 current ratio provide a cushion, debt-to-equity of 1.59 and a debt ratio of 0.48 mean leverage is meaningful. Revenue is highly concentrated in the LEU segment, which accounted for the majority of Q1 2026 revenue, and the pending expiration of Russian supply contracts could disrupt the fuel supply chain. Additionally, gross margins have been volatile, swinging from -5.7% in Q3 2025 to 38.7% in Q1 2026, reflecting mix shifts and execution risk.
Market and competitive risks are substantial. The stock trades at a premium valuation (9.72x PS, 32.97x EV/EBITDA) relative to peers, leaving it vulnerable to multiple compression if growth disappoints. With a beta of 1.334, the stock is 33% more volatile than the market, amplifying downside during sector rotations. The lack of direct U.S. competitors is a double-edged sword: while it confers monopoly-like pricing power, it also means any technological breakthrough in HALEU production by foreign entities or alternative fuel designs could erode Centrus's advantage. Recent news highlights the AI-nuclear narrative, but also warns of execution risks and Russian contract expiration, which could trigger further selling.
The worst-case scenario involves a breakdown below the 52-week low of $142.13, which is only 6.7% below the current price. If the HALEU ramp is delayed, Russian contracts expire without replacement, and cash burn continues, the stock could retest its 52-week low and potentially fall further. The analyst low target of $168.77 is above the current price, but in a severe downturn, the stock could drop to the $100-$120 range, representing a 21-34% decline from current levels. The 66.4% maximum drawdown from the peak illustrates the severe capital impairment risk, and a worst-case scenario could see an investor lose 35% or more from the current price.
FAQ
The key risks are: 1) Financial: negative free cash flow of -$61.4 million and a $70.7 million inventory build, which could force another equity raise. 2) Operational: execution delays in HALEU production and the pending expiration of Russian supply contracts. 3) Market: high valuation (9.72x PS) and a beta of 1.334, making the stock vulnerable to multiple compression. 4) Competitive: potential technological breakthroughs in HALEU production by foreign entities. The most severe risk is a breakdown below the 52-week low of $142.13, which could trigger a further 20-30% decline.
Our 12-month forecast has three scenarios: Bull (25% probability) with a target range of $280-$340, assuming successful HALEU scaling and revenue acceleration; Base (50% probability) with a target range of $200-$250, assuming steady execution and 10-15% revenue growth; and Bear (25% probability) with a target range of $120-$168, assuming execution delays and a breakdown below the 52-week low. The base case is most likely, anchored by the analyst average target of $248.28, but the wide range reflects high uncertainty.
LEU appears overvalued on most metrics. It trades at a trailing PE of 56.1x, forward PE of 40.5x, PS of 9.72x, and EV/EBITDA of 32.97x, which are rich for a company growing revenue at only 4.9%. The forward PE implies 38% earnings growth, a high bar given the lumpy revenue pattern. Compared to its own history, the current PS of 9.72x is in the middle-to-lower portion of its historical band (which ranged from 3.59x to 75.8x), suggesting the stock has de-rated but is not yet at deep-value levels. The market is pricing in flawless execution of the HALEU ramp.
LEU is a high-risk, high-reward investment that is currently in a severe downtrend, down 44.1% YTD and sitting just 3.0% above its 52-week low of $142.13. The analyst consensus target of $248.28 implies 63% upside, but the wide target range ($168.77-$340.00) and heavy Neutral ratings suggest low conviction. The biggest downside risk is a breakdown below $142.13, which could lead to further losses. For risk-tolerant investors with a long time horizon, LEU could be a good buy on stabilization, but it is not suitable for conservative portfolios.
LEU is better suited for long-term investors who can tolerate volatility and have a time horizon of at least 3-5 years. The company is in a growth phase, with a unique HALEU monopoly and a $3.9 billion backlog, but it is not yet profitable on a cash flow basis and pays no dividend. The beta of 1.334 and 66.4% maximum drawdown make it unsuitable for short-term trading unless one is actively managing risk. A minimum holding period of 2-3 years is recommended to allow the HALEU ramp to materialize.